Searching for novel biomarkers and new therapeutic targets of diabetic nephropathy using proteomics approaches

Contributions to Nephrology

Volumn 160, Issue , 2008, Pages 37-52

  Thongboonkerd, V ^a,b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; DIABETIC NEPHROPATHY; HUMAN; METABOLISM; METHODOLOGY; PROTEOMICS; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; HUMANS; PROTEOMICS;

EID: 48949107451     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000125928     Document Type: Review

References (78)

1. Foley RN, Collins AJ: End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007;18:2644-2648.
2. Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408.
3. Chavers BM, Bilous RW, Ellis EN, Steffes MW, Mauer SM: Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 1989;320:966-970.
4. Fioretto P, Steffes MW, Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994;43:1358-1364.
5. Bangstad HJ, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Nyberg G, Frahm BS, Hanssen KF: Early glomerulopathy is present in young, type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36:523-529.
6. Comper WD, Osicka TM, Jerums G: High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis 2003;41:336-342.
7. Aebersold R: Constellations in a cellular universe. Nature 2003;422:115-116.
8. Candiano G, Musante L, Bruschi M, Petretto A, Santucci L, Del Boccio P, Pavone B, Perfumo F, Urbani A, Scolari F, Ghiggeri GM: Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol 2006;17:3139-3148.
9. Thongboonkerd V, Klein JB (eds): Proteomics in Nephrology. Contrib Nephrol. Basel, Karger, 2004, vol 141, pp 1-327.
10. Thongboonkerd V: Proteomics in Nephrology: Current Status and Future Directions. Am J Nephrol 2004;24:360-378.
11. Thongboonkerd V, Malasit P: Renal and urinary proteomics: Current applications and challenges. Proteomics 2005;5:1033-1042.
12. Thongboonkerd V: Proteomic analysis of renal diseases: Unraveling the pathophysiology and biomarker discovery. Expert Rev Proteomics 2005;2:349-366.
13. Thongboonkerd V: Recent progress in urinary proteomics. Proteomics Clin Appl 2007;1:780-791.
14. Thongboonkerd V: Practical points in urinary proteomics. J Proteome Res 2007;6:3881-3890.
15. Korc M: Diabetes mellitus in the era of proteomics. Mol Cell Proteomics 2003;2:399-404.
16. Sparre T, Bergholdt R, Nerup J, Pociot F: Application of genomics and proteomics in Type 1 diabetes pathogenesis research. Expert Rev Mol Diagn 2003;3:743-757.
17. Korc M: Update on diabetes mellitus. Dis Markers 2004;20:161-165.
18. Sparre T, Larsen MR, Heding PE, Karlsen AE, Jensen ON, Pociot F: Unraveling the pathogenesis of type 1 diabetes with proteomics: present and future directions. Mol Cell Proteomics 2005;4:441-457.
19. Basso D, Greco E, Fogar P, Pucci P, Flagiello A, Baldo G, Giunco S, Valerio A, Navaglia F, Zambon CF, Pedrazzoli S, Plebani M: Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin Chim Acta 2005;357:184-189.
20. Scott EM, Carter AM, Findlay JB: The application of proteomics to diabetes. Diab Vasc Dis Res 2005;2:54-60.
21. D'Hertog W, Mathieu C, Overbergh L: Type 1 diabetes: entering the proteomic era. Expert Rev Proteomics 2006;3:223-236.
22. Thongboonkerd V: Proteomic for diabetes research: An update and future perspectives. Expert Rev Endocrinol Metab 2006;1:507-515.
23. Thongboonkerd V, Barati MT, McLeish KR, Pierce WM, Epstein PN, Klein JB: Proteomics and diabetic nephropathy. Contrib Nephrol 2004;141:142-154.
24. Merchant ML, Klein JB: Proteomics and diabetic nephropathy. Curr Diab Rep 2005;5:464-469.
25. Rossing K: Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Dan Med Bull 2007;54:79-98.
26. Susztak K, Bottinger EP: Diabetic nephropathy: a frontier for personalized medicine. J Am Soc Nephrol 2006;17:361-367.
27. Merchant ML, Klein JB: Proteomics and diabetic nephropathy. Semin Nephrol 2007;27:627-636.
28. Fradkin J: NIDDK Encourages Technology Research in Diabetes. Diabetes Technol Ther 2002;4:713-716.
29. Klein E, Klein JB, Thongboonkerd V: Two-dimensional gel electrophoresis: a fundamental tool for expression proteomics studies. Contrib Nephrol 2004;141:25-39.
30. Thongboonkerd V, Barati MT, McLeish KR, Benarafa C, Remold-O'Donnell E, Zheng S, Rovin BH, Pierce WM, Epstein PN, Klein JB: Alterations in the renal elastin-elastase system in Type 1 diabetic nephropathy identified by proteomic analysis. J Am Soc Nephrol 2004;15:650-662.
31. Thongboonkerd V, Zheng S, McLeish KR, Epstein PN, Klein JB: Proteomic identification and immunolocalization of increased renal calbindin-D28k expression in OVE26 diabetic mice. Rev Diab Stud 2005;2:17-24.
32. Thongboonkerd V, Barati MT, McLeish KR, Rovin BH, Pierce WM, Epstein PN, Klein JB: Altered elastase inhibitor and elastin expression in Type 2 diabetic kidneys defined by proteomic analysis. J Am Soc Nephrol 2003;14(suppl):600A.
33. Tilton RG, Haidacher SJ, Lejeune WS, Zhang X, Zhao Y, Kurosky A, Brasier AR, Denner L: Diabetes-induced changes in the renal cortical proteome assessed with two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2007;7:1729-1742.
34. Ramachandra Rao SP, Wassell R, Shaw MA, Sharma K: Profiling of human mesangial cell subproteomes reveals a role for calmodulin in glucose uptake. Am J Physiol Renal Physiol 2007;292:F1182-F1189.
35. Barati MT, Merchant ML, Kain AB, Jevans AW, McLeish KR, Klein JB: Proteomic analysis defines altered cellular redox pathways and advanced glycation end-product metabolism in glomeruli of db/db diabetic mice. Am J Physiol Renal Physiol 2007;293:F1157-F1165.
36. Thongboonkerd V, Klein JB, Jevans AW, McLeish KR: Urinary proteomics and biomarker discovery for glomerular diseases. Contrib Nephrol 2004;141:292-307.
37. Varghese SA, Powell TB, Budisavljevic MN, Oates JC, Raymond JR, Almeida JS, Arthur JM: Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol 2007;18:913-922.
38. Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR, Kim CW: Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 2007;6:735-743.
39. Cho EH, Kim MR, Kim HJ, Lee DY, Kim PK, Choi KM, Ryu OH, Kim CW: The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis. Proteomics Clin Appl 2007;1:352-361.
40. Lilley KS, Friedman DB: All about DIGE: quantification technology for differential-display 2Dgel proteomics. Expert Rev Proteomics 2004;1:401-409.
41. Marouga R, David S, Hawkins E: The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 2005;382:669-678.
42. Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, Wassell R, Shaw MA, RamachandraRao SP: Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005;5:2648-2655.
43. Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, Dakshinamurthy KV, Roberts CT Jr, Nagalla SR: Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007;30:629-637.
44. Kolch W, Neususs C, Pelzing M, Mischak H: Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24:959-977.
45. Simpson DC, Smith RD: Combining capillary electrophoresis with mass spectrometry for applications in proteomics. Electrophoresis 2005;26:1291-1305.
46. Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, Danne T, Haller H, Fliser D, Mischak H: Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications 2005;19:223-232.
47. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Knueppel S, Haller H, Fliser D: Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) 2004;107:485-495.
48. Fung E, Diamond D, Simonsesn AH, Weinberger SR: The use of SELDI ProteinChip array technology in renal disease research. Methods Mol Med 2003;86:295-312.
49. Petricoin EF, Liotta LA: Clinical proteomics: application at the bedside. Contrib Nephrol 2004;141:93-103.
50. Papale M, Pedicillo MC, Thatcher BJ, Di Paolo S, Lo ML, Bufo P, Rocchetti MT, Centra M, Ranieri E, Gesualdo L: Urine profiling by SELDI-TOF/MS: monitoring of the critical steps in sample collection, handling and analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2007;856:205-213.
51. Poon TC: Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007;4:51-65.
52. Cho WC, Yip TT, Chung WS, Leung AW, Cheng CH, Yue KK: Differential expression of proteins in kidney, eye, aorta, and serum of diabetic and non-diabetic rats. J Cell Biochem 2006;99:256-268.
53. Dihazi H, Muller GA, Lindner S, Meyer M, Asif AR, Oellerich M, Strutz F: Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem 2007;53:1636-1645.
54. Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R: Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007;30:638-643.
55. Tudos AJ, Besselink GJ, Schasfoort RB: Trends in miniaturized total analysis systems for point-of-care testing in clinical chemistry. Lab Chip 2001;1:83-95.
56. Verpoorte E: Microfluidic chips for clinical and forensic analysis. Electrophoresis 2002;23:677-712.
57. Whitesides GM: The origins and the future of microfluidics. Nature 2006;442:368-373.
58. Lion N, Reymond F, Girault HH, Rossier JS: Why the move to microfluidics for protein analysis? Curr Opin Biotechnol 2004;15:31-37.
59. Srinivasan V, Pamula VK, Fair RB: An integrated digital microfluidic lab-on-a-chip for clinical diagnostics on human physiological fluids. Lab Chip 2004;4:310-315.
60. Minas G, Wolffenbuttel RF, Correia JH: A lab-on-a-chip for spectrophotometric analysis of biological fluids. Lab Chip 2005;5:1303-1309.
61. Thongboonkerd V, Songtawee N, Sritippayawan S: Urinary proteome profiling using microfluidic technology on a chip. J Proteome Res 2007;6:2011-2018.
62. Rosca MG, Mustata TG, Kinter MT, Ozdemir AM, Kern TS, Szweda LI, Brownlee M, Monnier VM, Weiss MF: Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005;289:F420-F430.
63. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ: Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylarginine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. J Biol Chem 1994;269:32299-32305.
64. Thornalley PJ, Westwood M, Lo TW, McLellan AC: Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. Contrib Nephrol 1995;112:24-31.
65. Schmitt S, Linder M, Standker L, Hammes HP, Preissner KT: Identification of CML-modified Proteins in Hemofiltrate of Diabetic Patients by Proteome Analysis. Exp Clin Endocrinol Diabetes 2007;116:26-34.
66. Lim CK, Lord G: Current developments in LC-MS for pharmaceutical analysis. Biol Pharm Bull 2002;25:547-557.
67. Iyer RA, Malhotra B, Khan S, Mitroka J, Bonacorsi S Jr, Waller SC, Rinehart JK, Kripalani K: Comparative Biotransformation of Radiolabeled [(14)C]Omapatrilat and Stable-labeled [(13)C(2)]Omapatrilat after Oral Administration to Rats, Dogs, and Humans. Drug Metab Dispos 2003;31:67-75.
68. Kim Y, Hwang J, Kim M, Lee W: Determination of Tripamide in human urine by high-performance liquid chromatography and high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2003;17:301-306.
69. Garzotti M: Lacidipine, a potential peroxynitrite scavenger: investigation of activity by liquid chromatography and mass spectrometry. Rapid Commun Mass Spectrom 2003;17:272-278.
70. Jain KK: Proteomics and drug discovery. Contrib Nephrol 2004;141:308-327.
71. Chapman AB, Schwartz GL, Boerwinkle E, Turner ST: Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int 2002;61:1047-1055.
72. Trotta R, Donati MB, Iacoviello L: Trends in pharmacogenomics of drugs acting on hypertension. Pharmacol Res 2004;49:351-356.
73. Cadman PE, O'Connor DT: Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003;12:61-70.
74. Edvardsson U, Brockenhuus VL, Panfilov O, Nystrom AC, Nilsson F, Dahllof B: Hepatic protein expression of lean mice and obese diabetic mice treated with peroxisome proliferator-activated receptor activators. Proteomics 2003;3:468-478.
75. Sanchez JC, Converset V, Nolan A, Schmid G, Wang S, Heller M, Sennitt MV, Hochstrasser DF, Cawthorne MA: Effect of rosiglitazone on the differential expression of diabetes- associated proteins in pancreatic islets of C57Bl/6 lep/lep mice. Mol Cell Proteomics 2002;1:509-516.
76. Sanchez JC, Converset V, Nolan A, Schmid G, Wang S, Heller M, Sennitt MV, Hochstrasser DF, Cawthorne MA: Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 2003;3:1500-1520.
77. Rossing K, Mischak H, Walden M, Parving HH, Christensen CK, Hillmann M, Kaiser T: The impact of diabetic nephropathy and angiotensin II receptor blocker treatment on urinary polypeptide patterns in type 2 diabetic patients. Kidney Int 2005;68:193-205.
78. Diao WF, Chen WQ, Wu Y, Liu P, Xie XL, Li S, Shen PP, Ji J: Serum, liver, and kidney proteomic analysis for the alloxan-induced type I diabetic mice after insulin gene transfer of naked plasmid through electroporation. Proteomics 2006;6:5837-5845.